{"version":"1.0","provider_name":"Bordeaux Neurocampus","provider_url":"https:\/\/www.bordeaux-neurocampus.fr\/en\/","author_name":"Bezard Erwan","author_url":"https:\/\/www.bordeaux-neurocampus.fr\/en\/author\/erwan-bezardu-bordeaux-fr\/","title":"Managing Parkinson's disease: moving ON with NOP. - Bordeaux Neurocampus","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"AXozRdCiiI\"><a href=\"https:\/\/www.bordeaux-neurocampus.fr\/en\/article\/managing-parkinsons-disease-moving-on-with-nop\/\">Managing Parkinson&#8217;s disease: moving ON with NOP.<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.bordeaux-neurocampus.fr\/en\/article\/managing-parkinsons-disease-moving-on-with-nop\/embed\/#?secret=AXozRdCiiI\" width=\"600\" height=\"338\" title=\"&#8220;Managing Parkinson&#8217;s disease: moving ON with NOP.&#8221; &#8212; Bordeaux Neurocampus\" data-secret=\"AXozRdCiiI\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.bordeaux-neurocampus.fr\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","description":"1. Br J Pharmacol. 2020 Jan;177(1):28-47. doi: 10.1111\/bph.14893. Epub 2020 Jan 3. Managing Parkinson's disease: moving ON with NOP. Mercatelli D(1), Bezard E(2)(3), Eleopra R(4), Zaveri NT(5), Morari M(1). Author information: (1)Department of Medical Sciences, Section of Pharmacology, University of Ferrara and National Institute of Neuroscience, Ferrara, Italy. (2)Institut des Maladies Neurod\u00e9g\u00e9n\u00e9ratives, UMR 5293, Universit\u00e9 de Bordeaux, Bordeaux, France. (3)Institut des Maladies Neurod\u00e9g\u00e9n\u00e9ratives, Centre National de la Recherche Scientifique, UMR 5293, Bordeaux, France. (4)Neurology Unit 1, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. (5)Astraea Therapeutics, Medicinal Chemistry Division, Mountain View, California, USA. The opioid-like neuropeptide nociceptin\/orphanin FQ (N\/OFQ) and&hellip;"}